Neurocrine Biosciences (NASDAQ:NBIX) Stock Price Expected to Rise, Piper Sandler Analyst Says

Neurocrine Biosciences (NASDAQ:NBIX) had its price target lifted by analysts at Piper Sandler from $207.00 to $210.00 in a report released on Friday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Piper Sandler’s price target points to a potential upside of 25.70% from the company’s previous close.

A number of other analysts have also commented on the company. JPMorgan Chase & Co. lifted their target price on Neurocrine Biosciences from $177.00 to $185.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Wedbush upped their price target on Neurocrine Biosciences from $166.00 to $176.00 and gave the company an “outperform” rating in a report on Wednesday, May 6th. BMO Capital Markets lifted their price objective on Neurocrine Biosciences from $144.00 to $170.00 and gave the stock a “market perform” rating in a report on Monday, July 13th. Citigroup boosted their target price on Neurocrine Biosciences from $242.00 to $246.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Finally, Leerink Partners upped their target price on shares of Neurocrine Biosciences from $160.00 to $170.00 and gave the company an “outperform” rating in a research note on Wednesday, April 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $198.23.

Neurocrine Biosciences Trading Down 9.9%

Neurocrine Biosciences stock traded down $18.43 during mid-day trading on Friday, hitting $167.06. The company had a trading volume of 1,415,500 shares, compared to its average volume of 1,179,980. The stock’s 50 day moving average price is $167.61 and its two-hundred day moving average price is $146.25. Neurocrine Biosciences has a 12 month low of $122.14 and a 12 month high of $186.12. The company has a market capitalization of $16.80 billion, a PE ratio of 25.69, a price-to-earnings-growth ratio of 0.76 and a beta of 0.39.

Insider Activity at Neurocrine Biosciences

In related news, insider Jude Onyia sold 11,000 shares of the firm’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $160.25, for a total transaction of $1,762,750.00. Following the completion of the transaction, the insider directly owned 25,846 shares of the company’s stock, valued at approximately $4,141,821.50. This trade represents a 29.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Julie Cooke sold 36,937 shares of the firm’s stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $156.22, for a total value of $5,770,298.14. Following the transaction, the insider owned 22,374 shares of the company’s stock, valued at approximately $3,495,266.28. The trade was a 62.28% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 395,422 shares of company stock worth $62,448,693 in the last 90 days. Company insiders own 4.60% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. AQR Capital Management LLC lifted its position in shares of Neurocrine Biosciences by 18.0% during the fourth quarter. AQR Capital Management LLC now owns 3,271,706 shares of the company’s stock worth $462,652,000 after purchasing an additional 498,058 shares during the last quarter. Renaissance Technologies LLC grew its holdings in shares of Neurocrine Biosciences by 8.0% in the first quarter. Renaissance Technologies LLC now owns 2,418,897 shares of the company’s stock worth $318,665,000 after purchasing an additional 180,100 shares during the last quarter. Geode Capital Management LLC increased its stake in Neurocrine Biosciences by 1.7% in the 4th quarter. Geode Capital Management LLC now owns 2,059,282 shares of the company’s stock worth $291,342,000 after buying an additional 34,457 shares during the period. Los Angeles Capital Management LLC increased its stake in Neurocrine Biosciences by 7.4% in the 4th quarter. Los Angeles Capital Management LLC now owns 1,291,278 shares of the company’s stock worth $178,248,000 after buying an additional 88,522 shares during the period. Finally, Northern Trust Corp lifted its holdings in Neurocrine Biosciences by 31.9% during the 4th quarter. Northern Trust Corp now owns 1,221,184 shares of the company’s stock valued at $173,201,000 after buying an additional 295,470 shares in the last quarter. Institutional investors own 92.59% of the company’s stock.

Key Headlines Impacting Neurocrine Biosciences

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Q2 results exceeded expectations. Neurocrine reported adjusted earnings of $2.85 per share, above the $2.26 Zacks consensus estimate, while revenue reached $959 million versus analysts’ $891 million forecast. Revenue increased approximately 39% year over year. Neurocrine Biosciences Surpasses Q2 Earnings and Revenue Estimates
• Positive Sentiment: Management raised full-year INGREZZA guidance. 2026 net product sales guidance for INGREZZA was increased to $2.825 billion-$2.875 billion. Second-quarter INGREZZA sales rose 15% to $716 million, while CRENESSITY generated $184 million and newly acquired VYKAT XR contributed $54 million following the Soleno Therapeutics acquisition. Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results
• Positive Sentiment: Needham increased its price target. Needham & Company raised its target from $200 to $204 and maintained a “Buy” rating, signaling continued confidence in NBIX’s earnings growth and commercial outlook. Benzinga
• Neutral Sentiment: Analyst sentiment remains favorable. NBIX carries a consensus “Moderate Buy” rating and an average price target of approximately $194, although investors may be looking for additional upside after the stock’s recent strength.
• Negative Sentiment: A director sold shares. Leslie Norwalk sold 1,250 shares worth approximately $227,513, reducing her holdings by 44%. The sale occurred under a pre-arranged Rule 10b5-1 plan, which reduces its significance as a discretionary bearish signal. SEC insider transaction filing

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.